Fotemustine plus dacarbazine for malignant melanoma
Identifieur interne : 000A13 ( Main/Exploration ); précédent : 000A12; suivant : 000A14Fotemustine plus dacarbazine for malignant melanoma
Auteurs : Marie-F Avril [France] ; Jean Bonneterre [France] ; Didier Cupissol [France] ; Jean-J Grob [France] ; Bernard Kalis [France] ; Pierre Fumoleau [France] ; Pierre Kerbrat [France] ; Lucien Israel [France] ; Pierre Fargeot [France] ; Daniel Lambert [France] ; Michelle Delaunay [France] ; Brigitte Dreno [France] ; Catherine Vilmer [France] ; Jean-P Bizzari [France] ; Véronique Cour [France]Source :
- European Journal of Cancer [ 0959-8049 ] ; 1992.
English descriptors
- Teeft :
- Alkaline phosphatases, Biometric parameters, Cancer chemother, Centre, Cerebral lesions, Cerebral metastases, Chemotherapy, Clinical trials, Combination chemotherapy, Complete response, Complete responses, Dacarbazine, Disease progression, Dominant metastatic site, Early death, Eurj cancer, Evaluable, Evaluable patients, Final evaluation, Fotemustine, Grade leukopenia, Haematological, Haematological toxicity, High performance, Hopital, Induction cycle, Lesion, Limb perfusion, Maintenance cycle, Malignant, Malignant melanoma, Median, Median days, Median duration, Median durations, Median nadir, Median survival time, Melanoma, Melphalan, Metastasis, Metastatic, Metastatic melanoma, Monotherapy, Natural history, Objective responses, Overall response rate, Partial response, Partial responses, Present series, Prognostic factors, Regimen, Response range, Response rate, Response rates, Toxicity, Visceral lesions, Visceral metastases.
Abstract
Abstract: 119 patients with metastatic melanoma received fotemustine 100 mg/m2 on days 1 and 8 and dacarbazine 250 mg/m2 on days 15–18. After a 5-week rest, fotemustine 100 mg/m2 on day 1 and dacarbazine 250 mg/m2 on days 2–5 was given every 3–4 weeks. 12 complete responses (11.6%) and 16 partial responses were observed in 103 evaluable patients (response rate 27.2%). The median duration of response was 21.5+ weeks (8+ to 53+). The response rate was 26.3% in CNS, 18.2% in visceral sites and 37.5% in non-visceral sites. The toxicity was mainly haematological: grade III–IV leukopenia in 27.4% and thrombocytopenia in 23.4%. The response rate was lower than that in 63 patients previously reported. The present series had a higher median age (54 vs. 40 years) without any differences in other population variables. However, activity on CNS metastases and on non-visceral sites was confirmed. Haematological toxicity was about 50% lower than that with fotemustine alone. Hence, this is an active outpatient regiment for metastatic melanoma, especially against cerebral and non-visceral metastases.
Url:
DOI: 10.1016/0959-8049(92)90008-P
Affiliations:
- France
- Aquitaine, Bourgogne, Bourgogne-Franche-Comté, Champagne-Ardenne, Grand Est, Hauts-de-France, Languedoc-Roussillon, Nord-Pas-de-Calais, Nouvelle-Aquitaine, Occitanie (région administrative), Pays de la Loire, Provence-Alpes-Côte d'Azur, Région Bretagne, Île-de-France
- Bobigny, Bordeaux, Dijon, Lille, Marseille, Montpellier, Nantes, Reims, Rennes, Villejuif
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000845
- to stream Istex, to step Curation: 000844
- to stream Istex, to step Checkpoint: 000704
- to stream Main, to step Merge: 000A23
- to stream Main, to step Curation: 000A13
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Fotemustine plus dacarbazine for malignant melanoma</title><author><name sortKey="Avril, Marie F" sort="Avril, Marie F" uniqKey="Avril M" first="Marie-F" last="Avril">Marie-F Avril</name></author><author><name sortKey="Bonneterre, Jean" sort="Bonneterre, Jean" uniqKey="Bonneterre J" first="Jean" last="Bonneterre">Jean Bonneterre</name></author><author><name sortKey="Cupissol, Didier" sort="Cupissol, Didier" uniqKey="Cupissol D" first="Didier" last="Cupissol">Didier Cupissol</name></author><author><name sortKey="Grob, Jean J" sort="Grob, Jean J" uniqKey="Grob J" first="Jean-J" last="Grob">Jean-J Grob</name></author><author><name sortKey="Kalis, Bernard" sort="Kalis, Bernard" uniqKey="Kalis B" first="Bernard" last="Kalis">Bernard Kalis</name></author><author><name sortKey="Fumoleau, Pierre" sort="Fumoleau, Pierre" uniqKey="Fumoleau P" first="Pierre" last="Fumoleau">Pierre Fumoleau</name></author><author><name sortKey="Kerbrat, Pierre" sort="Kerbrat, Pierre" uniqKey="Kerbrat P" first="Pierre" last="Kerbrat">Pierre Kerbrat</name></author><author><name sortKey="Israel, Lucien" sort="Israel, Lucien" uniqKey="Israel L" first="Lucien" last="Israel">Lucien Israel</name></author><author><name sortKey="Fargeot, Pierre" sort="Fargeot, Pierre" uniqKey="Fargeot P" first="Pierre" last="Fargeot">Pierre Fargeot</name></author><author><name sortKey="Lambert, Daniel" sort="Lambert, Daniel" uniqKey="Lambert D" first="Daniel" last="Lambert">Daniel Lambert</name></author><author><name sortKey="Delaunay, Michelle" sort="Delaunay, Michelle" uniqKey="Delaunay M" first="Michelle" last="Delaunay">Michelle Delaunay</name></author><author><name sortKey="Dreno, Brigitte" sort="Dreno, Brigitte" uniqKey="Dreno B" first="Brigitte" last="Dreno">Brigitte Dreno</name></author><author><name sortKey="Vilmer, Catherine" sort="Vilmer, Catherine" uniqKey="Vilmer C" first="Catherine" last="Vilmer">Catherine Vilmer</name></author><author><name sortKey="Bizzari, Jean P" sort="Bizzari, Jean P" uniqKey="Bizzari J" first="Jean-P" last="Bizzari">Jean-P Bizzari</name></author><author><name sortKey="Cour, Veronique" sort="Cour, Veronique" uniqKey="Cour V" first="Véronique" last="Cour">Véronique Cour</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5FBA56325E17E2F1F107DCCE3C6131B8BF9E9A24</idno><date when="1992" year="1992">1992</date><idno type="doi">10.1016/0959-8049(92)90008-P</idno><idno type="url">https://api.istex.fr/document/5FBA56325E17E2F1F107DCCE3C6131B8BF9E9A24/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000845</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000845</idno><idno type="wicri:Area/Istex/Curation">000844</idno><idno type="wicri:Area/Istex/Checkpoint">000704</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000704</idno><idno type="wicri:doubleKey">0959-8049:1992:Avril M:fotemustine:plus:dacarbazine</idno><idno type="wicri:Area/Main/Merge">000A23</idno><idno type="wicri:Area/Main/Curation">000A13</idno><idno type="wicri:Area/Main/Exploration">000A13</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Fotemustine plus dacarbazine for malignant melanoma</title><author><name sortKey="Avril, Marie F" sort="Avril, Marie F" uniqKey="Avril M" first="Marie-F" last="Avril">Marie-F Avril</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Institut Gustave Roussy, Service de Dermatologie, 39, rue Camille Desmoulins, 94805 Villejuif Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Villejuif</settlement></placeName></affiliation></author><author><name sortKey="Bonneterre, Jean" sort="Bonneterre, Jean" uniqKey="Bonneterre J" first="Jean" last="Bonneterre">Jean Bonneterre</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Centre Oscar Lambret, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Cupissol, Didier" sort="Cupissol, Didier" uniqKey="Cupissol D" first="Didier" last="Cupissol">Didier Cupissol</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Centre Val d'Aurelle, Montpellier</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Grob, Jean J" sort="Grob, Jean J" uniqKey="Grob J" first="Jean-J" last="Grob">Jean-J Grob</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Sainte-Marguerite, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Kalis, Bernard" sort="Kalis, Bernard" uniqKey="Kalis B" first="Bernard" last="Kalis">Bernard Kalis</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Sébastopol, Reims</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Champagne-Ardenne</region><settlement type="city">Reims</settlement></placeName></affiliation></author><author><name sortKey="Fumoleau, Pierre" sort="Fumoleau, Pierre" uniqKey="Fumoleau P" first="Pierre" last="Fumoleau">Pierre Fumoleau</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Centre René Gauducheau, Nantes</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Kerbrat, Pierre" sort="Kerbrat, Pierre" uniqKey="Kerbrat P" first="Pierre" last="Kerbrat">Pierre Kerbrat</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Centre Eugène Marquis, Rennes</wicri:regionArea><placeName><region type="region">Région Bretagne</region><region type="old region">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Israel, Lucien" sort="Israel, Lucien" uniqKey="Israel L" first="Lucien" last="Israel">Lucien Israel</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Avicenne, Bobigny</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Bobigny</settlement></placeName></affiliation></author><author><name sortKey="Fargeot, Pierre" sort="Fargeot, Pierre" uniqKey="Fargeot P" first="Pierre" last="Fargeot">Pierre Fargeot</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Centre Georges François Leclerc, Dijon</wicri:regionArea><placeName><region type="region">Bourgogne-Franche-Comté</region><region type="old region">Bourgogne</region><settlement type="city">Dijon</settlement></placeName></affiliation></author><author><name sortKey="Lambert, Daniel" sort="Lambert, Daniel" uniqKey="Lambert D" first="Daniel" last="Lambert">Daniel Lambert</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>C.H.R.U.—Hôpital du bocage, Dijon</wicri:regionArea><placeName><region type="region">Bourgogne-Franche-Comté</region><region type="old region">Bourgogne</region><settlement type="city">Dijon</settlement></placeName></affiliation></author><author><name sortKey="Delaunay, Michelle" sort="Delaunay, Michelle" uniqKey="Delaunay M" first="Michelle" last="Delaunay">Michelle Delaunay</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Pellegrin Tripode, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Dreno, Brigitte" sort="Dreno, Brigitte" uniqKey="Dreno B" first="Brigitte" last="Dreno">Brigitte Dreno</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>C.H.U. Hotel-Dieu, Nantes</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Vilmer, Catherine" sort="Vilmer, Catherine" uniqKey="Vilmer C" first="Catherine" last="Vilmer">Catherine Vilmer</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Centre René Huguenin, Saint-Cloud</wicri:regionArea><wicri:noRegion>Saint-Cloud</wicri:noRegion><wicri:noRegion>Saint-Cloud</wicri:noRegion></affiliation></author><author><name sortKey="Bizzari, Jean P" sort="Bizzari, Jean P" uniqKey="Bizzari J" first="Jean-P" last="Bizzari">Jean-P Bizzari</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherches Internationales Servier, Courbevoie</wicri:regionArea><wicri:noRegion>Courbevoie</wicri:noRegion><wicri:noRegion>Courbevoie</wicri:noRegion></affiliation></author><author><name sortKey="Cour, Veronique" sort="Cour, Veronique" uniqKey="Cour V" first="Véronique" last="Cour">Véronique Cour</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherches Internationales Servier, Courbevoie</wicri:regionArea><wicri:noRegion>Courbevoie</wicri:noRegion><wicri:noRegion>Courbevoie</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Cancer</title><title level="j" type="abbrev">EJC</title><idno type="ISSN">0959-8049</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1992">1992</date><biblScope unit="volume">28</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1807">1807</biblScope><biblScope unit="page" to="1811">1811</biblScope></imprint><idno type="ISSN">0959-8049</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0959-8049</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Alkaline phosphatases</term><term>Biometric parameters</term><term>Cancer chemother</term><term>Centre</term><term>Cerebral lesions</term><term>Cerebral metastases</term><term>Chemotherapy</term><term>Clinical trials</term><term>Combination chemotherapy</term><term>Complete response</term><term>Complete responses</term><term>Dacarbazine</term><term>Disease progression</term><term>Dominant metastatic site</term><term>Early death</term><term>Eurj cancer</term><term>Evaluable</term><term>Evaluable patients</term><term>Final evaluation</term><term>Fotemustine</term><term>Grade leukopenia</term><term>Haematological</term><term>Haematological toxicity</term><term>High performance</term><term>Hopital</term><term>Induction cycle</term><term>Lesion</term><term>Limb perfusion</term><term>Maintenance cycle</term><term>Malignant</term><term>Malignant melanoma</term><term>Median</term><term>Median days</term><term>Median duration</term><term>Median durations</term><term>Median nadir</term><term>Median survival time</term><term>Melanoma</term><term>Melphalan</term><term>Metastasis</term><term>Metastatic</term><term>Metastatic melanoma</term><term>Monotherapy</term><term>Natural history</term><term>Objective responses</term><term>Overall response rate</term><term>Partial response</term><term>Partial responses</term><term>Present series</term><term>Prognostic factors</term><term>Regimen</term><term>Response range</term><term>Response rate</term><term>Response rates</term><term>Toxicity</term><term>Visceral lesions</term><term>Visceral metastases</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: 119 patients with metastatic melanoma received fotemustine 100 mg/m2 on days 1 and 8 and dacarbazine 250 mg/m2 on days 15–18. After a 5-week rest, fotemustine 100 mg/m2 on day 1 and dacarbazine 250 mg/m2 on days 2–5 was given every 3–4 weeks. 12 complete responses (11.6%) and 16 partial responses were observed in 103 evaluable patients (response rate 27.2%). The median duration of response was 21.5+ weeks (8+ to 53+). The response rate was 26.3% in CNS, 18.2% in visceral sites and 37.5% in non-visceral sites. The toxicity was mainly haematological: grade III–IV leukopenia in 27.4% and thrombocytopenia in 23.4%. The response rate was lower than that in 63 patients previously reported. The present series had a higher median age (54 vs. 40 years) without any differences in other population variables. However, activity on CNS metastases and on non-visceral sites was confirmed. Haematological toxicity was about 50% lower than that with fotemustine alone. Hence, this is an active outpatient regiment for metastatic melanoma, especially against cerebral and non-visceral metastases.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Aquitaine</li><li>Bourgogne</li><li>Bourgogne-Franche-Comté</li><li>Champagne-Ardenne</li><li>Grand Est</li><li>Hauts-de-France</li><li>Languedoc-Roussillon</li><li>Nord-Pas-de-Calais</li><li>Nouvelle-Aquitaine</li><li>Occitanie (région administrative)</li><li>Pays de la Loire</li><li>Provence-Alpes-Côte d'Azur</li><li>Région Bretagne</li><li>Île-de-France</li></region><settlement><li>Bobigny</li><li>Bordeaux</li><li>Dijon</li><li>Lille</li><li>Marseille</li><li>Montpellier</li><li>Nantes</li><li>Reims</li><li>Rennes</li><li>Villejuif</li></settlement></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Avril, Marie F" sort="Avril, Marie F" uniqKey="Avril M" first="Marie-F" last="Avril">Marie-F Avril</name></region><name sortKey="Bizzari, Jean P" sort="Bizzari, Jean P" uniqKey="Bizzari J" first="Jean-P" last="Bizzari">Jean-P Bizzari</name><name sortKey="Bonneterre, Jean" sort="Bonneterre, Jean" uniqKey="Bonneterre J" first="Jean" last="Bonneterre">Jean Bonneterre</name><name sortKey="Cour, Veronique" sort="Cour, Veronique" uniqKey="Cour V" first="Véronique" last="Cour">Véronique Cour</name><name sortKey="Cupissol, Didier" sort="Cupissol, Didier" uniqKey="Cupissol D" first="Didier" last="Cupissol">Didier Cupissol</name><name sortKey="Delaunay, Michelle" sort="Delaunay, Michelle" uniqKey="Delaunay M" first="Michelle" last="Delaunay">Michelle Delaunay</name><name sortKey="Dreno, Brigitte" sort="Dreno, Brigitte" uniqKey="Dreno B" first="Brigitte" last="Dreno">Brigitte Dreno</name><name sortKey="Fargeot, Pierre" sort="Fargeot, Pierre" uniqKey="Fargeot P" first="Pierre" last="Fargeot">Pierre Fargeot</name><name sortKey="Fumoleau, Pierre" sort="Fumoleau, Pierre" uniqKey="Fumoleau P" first="Pierre" last="Fumoleau">Pierre Fumoleau</name><name sortKey="Grob, Jean J" sort="Grob, Jean J" uniqKey="Grob J" first="Jean-J" last="Grob">Jean-J Grob</name><name sortKey="Israel, Lucien" sort="Israel, Lucien" uniqKey="Israel L" first="Lucien" last="Israel">Lucien Israel</name><name sortKey="Kalis, Bernard" sort="Kalis, Bernard" uniqKey="Kalis B" first="Bernard" last="Kalis">Bernard Kalis</name><name sortKey="Kerbrat, Pierre" sort="Kerbrat, Pierre" uniqKey="Kerbrat P" first="Pierre" last="Kerbrat">Pierre Kerbrat</name><name sortKey="Lambert, Daniel" sort="Lambert, Daniel" uniqKey="Lambert D" first="Daniel" last="Lambert">Daniel Lambert</name><name sortKey="Vilmer, Catherine" sort="Vilmer, Catherine" uniqKey="Vilmer C" first="Catherine" last="Vilmer">Catherine Vilmer</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/BernheimV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A13 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A13 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Psychologie
|area= BernheimV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:5FBA56325E17E2F1F107DCCE3C6131B8BF9E9A24
|texte= Fotemustine plus dacarbazine for malignant melanoma
}}
| This area was generated with Dilib version V0.6.33. |  |